Deflazacort - Marathon Pharmaceuticals

Drug Profile

Deflazacort - Marathon Pharmaceuticals

Alternative Names: 21 desacetyl DFZ prodrug; DFZ; Emflaza; MP-104

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Marathon Pharmaceuticals
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antipsoriatics; Antirheumatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Duchenne muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duchenne muscular dystrophy

Most Recent Events

  • 08 May 2017 PTC Therapeutics plans to launch Deflazacort in USA for Duchenne muscular dystrophy
  • 20 Apr 2017 Deflazacort - Marathon Pharmaceuticals licensed to PTC Therapeutics in USA
  • 06 Apr 2017 Launched for Duchenne muscular dystrophy (In adolescents, In children) in USA (PO, Suspension and PO, Tablet) before April 2017 - First Global Launch
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top